ZICCUM AB submits patent applications for improved operation of the LaminarPace system for commercial vaccine production
Ziccum's LaminarPace system for the production of temperature-stable vaccines is already protected by approved patents. However, during ongoing work to further develop and prepare LaminarPace for commercial production, a number of new, innovative solutions have been developed. By submitting two more patent applications for central design elements Ziccum intends to strengthen and extend the protection of the company's unique production method.Ziccum CEO Göran Conradson: "We are further expanding our Intellectual Property portfolio around LaminarPace, including key details that are important